Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
BACKGROUND
Lung cancer is 1 of the leading causes of cancer death worldwide, and the high mortality from this disease is caused mainly by the lack of efficient diagnostic strategies for early-stage lung cancer. The objective of the current study was to investigate the expression pattern and clinicopathologic significance of centromere protein H (CENP-H) in patients with nonsmall cell lung cancer (NSCLC).


METHODS
The expression profile of CENP-H in normal lung epithelial cells, NSCLC cell lines, NSCLC tissues, and adjacent noncancerous lung tissues were detected by reverse transcription-polymerase chain reaction (RT-PCR), real-time RT-PCR, and Western blot analysis. The expression level of CENP-H in 223 NSCLC tissues was measured by immunohistochemistry staining. Statistical analysis was performed to evaluate the clinicopathologic significance of CENP-H.


RESULTS
The expression level of CENP-H was much higher in cancer cell lines and lung cancer tissues than that in normal cells and adjacent noncancerous lung tissues, respectively. Immunohistochemical analysis revealed positive CENP-H expression in 118 of 223 NSCLC tissues (52.9%). Statistical analysis revealed that CENP-H expression was correlated strongly with clinical stage (P=.018), tumor classification (P=.03), and Ki-67 expression (P < .001). Patients with lower CENP-H expression had better overall survival than patients with higher CENP-H expression. Further analysis suggested that CENP-H could predict prognosis only in patients with early-stage disease. Multivariate analysis suggested that CENP-H expression was an independent prognostic marker for survival in patients with NSCLC.


CONCLUSIONS
The current results demonstrated that high CENP-H protein expression was related to poor outcome in patients with NSCLC. CENP-H may be used as a prognostic biomarker for patients lung patients, especially those with early-stage NSCLC.
Liao
Wen-Ting
WT
State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong, China.
Wang
Xi
X
Xu
Li-Hua
LH
Kong
Qing-Li
QL
Yu
Chun-Ping
CP
Li
Man-Zhi
MZ
Shi
Ling
L
Zeng
Mu-Sheng
MS
Song
Li-Bing
LB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002868:Chromosomal Proteins, Non-Histone / Q000032:analysis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008168:Lung / Q000378:metabolism; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C121933:CENPH protein, human; D002868:Chromosomal Proteins, Non-Histone